YLYanan Li

Yanan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanan Li has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Anan Xu

    Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China

    2 shared publications
  • Chang Yao

    Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China

    2 shared publications
  • Gang Shen

    Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, China

    2 shared publications
  • Peng Li

    Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

    2 shared publications
  • Tao Yang

    Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China

    2 shared publications
  • Xue Song

    Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China

    2 shared publications

Latest Publications

  • Open Access

    Tumor-Derived Extracellular Vesicles Combining ALOX15 and RSL3 Enhance Lipid Oxidation and Antitumor Activity

    by Mingyue Fan, Shiyao Yin, Zhijie Zhou, Ming Li, Yanan Li

    Background/Objectives: Enhancing lipid peroxide formation while impairing antioxidant defenses represents a promising strategy for ferroptosis-based cancer therapy. This study aimed to evaluate a tumor-derived extracellular vesicle (EV) formulation combining ALOX15-associated lipid oxidation with RSL3-mediated inhibition of GPX4. Methods: RSL3@ALOX15-MPs were prepared by associating the GPX4 inhibitor RSL3 with ALOX15-containing EVs derived from 4T1 tumor cells. The formulation was characterized, and its effects on lipid oxidation, cell viability, and ferroptosis-associated responses were evaluated in vitro. Antitumor efficacy, biodistribution, tumor immune-cell phenotypes, and preliminary tolerability were assessed in 4T1 tumor-bearing mice. Results: The formulation exhibited EV-associated characteristics and an RSL3 loading content of approximately 3.8% relative to MP protein mass. In 4T1 cells, RSL3@ALOX15-MPs increased BODIPY-C11 oxidation to approximately five times the PBS control level and reduced cell viability to approximately 30%, compared with approximately 60% following RSL3-MP treatment. Ferrostatin-1, liproxstatin-1, and deferoxamine partially rescued cell viability and attenuated lipid oxidation. RSL3-containing formulations reduced total glutathione peroxidase activity, while ALOX15 inhibition attenuated lipid oxidation and cytotoxicity. The combined formulation also resulted in lower cell viability than a physical mixture of the individual formulations. In vivo, RSL3@ALOX15-MPs increased tumor RSL3 accumulation, altered intratumoral immune-cell phenotypes and cytokine levels, inhibited tumor growth, and prolonged survival. Conclusions: Combining ALOX15-associated lipid oxidation with RSL3 delivery using tumor-derived EVs enhanced ferroptosis-associated cytotoxicity in vitro and demonstrated antitumor efficacy in the 4T1 tumor model. Further studies are required to establish GPX4-specific effects and the causal contributions of ferroptosis and immune responses to the in vivo therapeutic outcomes.

  • Open Access

    Engineering CXCL10-enriched macrophage-derived extracellular vesicles for T cell recruitment and immune remodeling in pancreatic cancer

    by Shiyao Yin, Ming Li, Yanan Li

    CXCL@MEVs reprogram TAMs and recruit cytotoxic T cells for PDAC immunotherapy. Image created with BioRender. Yanan, L. (2026). https://BioRender.com/7xmquit.

  • Open Access

    Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers

    by Zhijun Miao, Xue Song, Anan Xu, Chang Yao, Peng Li, Yanan Li, Tao Yang, Gang Shen

    Background: Activating the cytosolic innate immune sensor, the cGAS-STING pathway, holds great promise for enhancing antitumor immunity, particularly in combination with immune checkpoint inhibitors (ICIs). However, the clinical application of STING agonists is often hindered by poor tumor accumulation, limited cellular uptake, and rapid clearance. To address these challenges, we developed a human serum albumin (HSA)-based nanoreactor system for the efficient delivery of the STING agonist SR-717, aiming to improve its antitumor efficacy. Methods: Using a biomineralization technique, we encapsulated SR-717 within HSA nanocages to form SH-NPs. These nanoparticles were characterized in terms of size, stability, and cellular uptake, and their ability to activate the STING pathway was assessed in both in vitro and in vivo models, including freshly isolated human renal tumor tissues. In vivo antitumor efficacy was evaluated in a murine renal tumor model, and immune responses were measured. Results: SH-NPs exhibited enhanced stability, efficient cellular uptake, and superior tumor accumulation compared to free SR-717. They robustly activated the STING pathway, as evidenced by increased phosphorylation of TBK1 and IRF3, along with elevated IFN-β production. Additionally, SH-NPs reshaped the immunosuppressive tumor microenvironment, promoting T-cell-mediated immunity and improving the therapeutic efficacy of checkpoint blockade in murine models. The validation in human renal tumor tissues further highlighted their potential for clinical translation. Importantly, SH-NPs were well tolerated with minimal systemic toxicity. Conclusions: This study underscores the potential of HSA-based nanoparticles for the targeted delivery of STING agonists, effectively enhancing antitumor immunity and improving cancer immunotherapy outcomes. SH-NPs offer a promising solution to the limitations of current STING agonists in clinical settings.


  • Open Access

    Targeted Delivery of STING agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers

    by Zhijun Miao, Xue Song, Anan Xu, Chang Yao, Peng Li, Yanan Li, Tao Yang, Gang Shen

    Activating the cytosolic innate immune sensor cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway via natural and synthetic agonists holds great potential for priming robust antitumor immunity. However, the effectiveness of STING agonists is often impeded by the insufficient tumor accumulation, poor cellular entry, and rapid clearance, thus leading to difficulty of their clinic translation. Herein, we apply the human serum albumin as the single-molecule nanoreactor to encapsulate SR-717 (SH-NPs) for enhanced targeting delivery efficiency and biological potency. SH-NPs with rational size distribution exhibited superior serum stability, considerable cellular uptake and abundant tumor accumulation, thus increasing the STING signaling including phosphorylation of STING-associated proteins (TBK1, IRF3), and cytokines secretion inside tumor region. Subsequently, SH-NPs remarkably reshape the immunosuppressive tumor microenvironment into an immunogenic one that boosts antitumor T-cell immunity and improves the therapeutic efficacy of checkpoint blockade against murine tumors. We also validate SH-NPs in freshly isolated human renal tumor tissues to highlight their clinic translation capability. These findings pave the way towards targeted STING agonist delivery for reinvigorated immunotherapy of intractable cancers.